|
| |
York Pharma - Announcement
date for Interims and update
Hitchin, UK, 31st March
2006: York Pharma, the AIM-listed (AIM:YRK) strategic acquirer, developer
and marketer of pharmaceutical products in the field of dermatology, announces
that its interim results for the 6 months ending 31st March 2006 will be
released at 7am on the 3rd May 2006. An analyst’s conference call is also
planned.
Terry Sadler, Chief Executive, commented:
'The business remains on track in all areas and is continuing to deliver on its
stated milestones. All R & D programmes are progressing well, cash reserves are
as expected, and we are engaged actively in our pre-launch planning activities
for Abasol™, which is scheduled for its first international launch in the United
Kingdom in Q4 of this year. The production of raw material has been completed
and pilot batches of finished product have been manufactured in Germany.
We are also seeking actively to bolster our pipeline in the UK in parallel with
the launch of Abasol™ by acquiring a suitable revenue producing dermatological
product which can be promoted in conjunction with Abasol™. Flexible sales force
options and partnering are also under consideration’.
--ENDS--
For more information please contact:
York Pharma plc
Tel: +44 (0) 870 066 4453
Terry Sadler, Chief Executive Officer
Northbank Communications
Tel: +44 (0) 207 886 8150
Emma Palmer (financial enquiries)
Rowan Minnion (media enquiries)
Notes to editors:
About York Pharma plc
York Pharma is an AIM-listed strategic acquirer, developer and marketer of
pharmaceutical products in the field of dermatology. Its portfolio now embraces
skin diseases that make up more than 75% of the global $10.4bn dermatology
market, and its lead product, Abasol™ for the treatment of fungal infections of
the skin, has been filed for European marketing approval, whilst its psoriasis (Vampex™)
and eczema and dermatitis (Sabarep™) products have progressed to Phase II
clinical development. For further information, please go to www.yorkpharma.com
| |
|
